Tobacco Plant Engineered to Produce Five Psychedelics at Once

Published April 2026 · Psilocybin Science & News

Tobacco's Bad Reputation — and Why It Is Not the Whole Story

When most people hear the word "tobacco," they think of cigarettes, nicotine addiction, and lung cancer. That reputation is well deserved. Commercial cigarettes contain thousands of chemical additives that are specifically added to increase nicotine delivery and make the product more addictive. The harm is real and well documented. However, that reputation belongs to the product — not entirely to the plant itself.

Nicotiana species belong to the nightshade family, closely related to tomatoes, peppers, and potatoes. In its natural, unprocessed form, tobacco has a long history in indigenous American cultures — not as a recreational drug, but as a sacred medicine used in ceremony, healing, and spiritual practice. Nicotiana rustica, for example, was used by Amazonian healers in ritual and purging. In other words, the plant itself was never the problem. What the tobacco industry made of it was.

Moreover, the tobacco plant used in this study is not even Nicotiana tabacum, the common commercial variety. Instead, researchers worked with Nicotiana benthamiana — a wild Australian relative used almost exclusively in plant biology laboratories. It grows quickly, is easy to modify genetically, and has no commercial use at all. Scientists have used it as a molecular factory for decades, producing everything from flu vaccine proteins to malaria drugs. Now it has been brought into the psychedelic science story as well.

How Scientists Engineered a Tobacco Plant to Produce Psychedelics

The research team, led by plant scientist Asaph Aharoni at the Weizmann Institute of Science in Israel, started by solving a puzzle that had puzzled chemists for many years: the complete step-by-step chemical pathway that plants use to make DMT. After careful investigation, they found the missing enzymes in Psychotria viridis (Chacruna) — the plant used in ayahuasca brews — and in Acacia acuminata, an Australian tree species.

Once the team had mapped the DMT pathway, they noticed something elegant. The building blocks for DMT, psilocybin, bufotenine, and 5-MeO-DMT all start from the same amino acid: tryptophan. Although these pathways evolved separately across fungi, plants, and animals over millions of years, they share the same basic chemical skeleton. That shared logic made it possible to combine all of them in one place.

By inserting nine genes — taken from mushrooms, plants, a toad, rice, and bacteria — into N. benthamiana leaves using a standard laboratory technique called agroinfiltration, the team got this engineered tobacco plant to produce all five psychedelics at once. The best individual yields were 205 micrograms of psilocybin and 89 micrograms of DMT per gram of fresh plant material. Those numbers are modest by pharmaceutical standards, but as a proof of concept they are significant. You can read the full study details at ScienceAlert.

A Bonus Discovery: New Psychedelic Molecules That Do Not Exist in Nature

Beyond the five natural compounds, the research team went a step further. By adding bacterial enzymes called halogenases to the tobacco plant system, they also produced chlorinated and brominated versions of DMT and psilocybin. These new molecules do not exist anywhere in nature. Several similar halogenated analogs have shown promising effects in earlier pharmacological research — some with antidepressant-like activity, others with different receptor binding profiles.

Importantly, the engineered tobacco plant generated these entirely new molecules without any need for separate chemical synthesis. In drug development, researchers normally have to synthesize hundreds of candidate molecules one by one. As a result, a plant platform that produces whole libraries of psychedelic analogs in a single growing cycle could dramatically speed up the search for new medicines. New Scientist covers this aspect in further detail.

Natural vs. Synthetic Psilocybin: Does the Source Matter?

This question sits at the heart of any honest discussion about psychedelic medicine. To understand it, we need to go back to one of the most important moments in the history of magic mushrooms.

In 1958, biochemist Albert Hofmann — the same scientist who discovered LSD — isolated and synthesized psilocybin from Psilocybe mexicana mushrooms. He tested the synthetic compound on himself and reported that the effects were indistinguishable from eating the mushrooms directly. He then offered his synthetic psilocybin to María Sabina, the Mazatec curandera who had spent her entire life working with sacred mushrooms. She confirmed that the pills produced the same experience as her niños santos — her "little saints," the mushrooms at the centre of her healing ceremonies. A molecule is a molecule, regardless of where it comes from.

Maria Sabina

That confirmation carries real weight. María Sabina was not analysing chemistry — she was assessing the medicine through the lens of decades of experience. She judged the two sources equivalent. What the Weizmann Institute has now opened is simply a third route to that same molecule: not a wild mushroom, not a chemical synthesis lab, but a living tobacco plant that grows psychedelics naturally from the soil, using sunlight, water, and a handful of inserted genes.

Why This Tobacco Plant Psychedelics Breakthrough Matters for Medicine

The clinical expansion of psilocybin therapy is creating real supply pressure around the world. For example, Compass Pathways is preparing a formal application to the US FDA for its synthetic psilocybin product COMP360, expected in the final quarter of 2026. Meanwhile, Oregon and Colorado already have legal supervised psilocybin frameworks in place. Furthermore, the Czech Republic became the first EU country to legally regulate psilocybin-assisted therapy in psychiatric clinics, effective 1 January 2026. In short, demand for pharmaceutical-grade psilocybin is growing faster than current production methods can easily meet.

At the same time, harvesting psilocybin mushrooms at industrial scale creates environmental concerns. Overharvesting of wild Psilocybe species, pressure on indigenous traditions, and supply inconsistency are all real problems. Similarly, the Sonoran Desert toad, the natural source of 5-MeO-DMT and bufotenine, is already under strain from ceremonial demand. A tobacco plant producing psychedelics through biosynthesis addresses these issues directly.

Specifically, the researchers point to three key advantages of the N. benthamiana platform:

Of course, the authors are clear that this is still a proof of concept. Scaling up to pharmaceutical-grade yields will require moving from temporary gene insertion to stable genetic transformation — tobacco plants that carry the new genes permanently in every cell. That work is already underway in research labs around the world.

The Bigger Picture: Plants as Psychedelic Factories

Psychedelics have always come from plants, fungi, and animals. Ayahuasca, for instance, combines DMT from Psychotria viridis (Chacruna) with MAO-inhibiting compounds from Banisteriopsis Caapi. Peyote provides mescaline from a cactus. Magic mushrooms provide psilocybin from Psilocybe species. The Sonoran Desert toad provides 5-MeO-DMT from its skin glands. Remarkably, these molecules all evolved independently across millions of years of separate biochemical history.

In essence, what the Weizmann study does is reunite those molecules in a single tobacco plant producing psychedelics — as if nature's separate experiments were running simultaneously in one living laboratory. As the researchers describe it, the work "blends catalytic functions across the tree of life." That is a striking phrase. Fungi, plants, and animals each found their own path to the same chemical territory, arriving at serotonin-binding molecules from completely different directions. Now, for the first time, we can trace all those paths back to a single starting point and run them together.

In addition, the study completed the long-missing DMT biosynthetic pathway in plants, identifying the specific enzymes in Psychotria viridis and Acacia acuminata that drive DMT production. This is foundational scientific knowledge with implications well beyond production. It explains, for instance, why DMT accumulates in P. viridis leaves but not in closely related plant species that simply lack the same enzyme activity. Another well-known DMT source is Mimosa hostilis (Jurema Preta), whose root bark contains high concentrations of the same compound.

What This Does Not Change — Yet

It is worth being honest about what this tobacco plant psychedelics research is — and what it is not. First, it is not a new drug ready for human use. Second, it is not a shortcut to legal access. And third, it is not a replacement for the careful therapeutic setting that makes psilocybin medicine work. Currently, the plant system produces compounds in microgram quantities inside research greenhouse conditions. Pharmaceutical yields, strict purity standards, and regulatory approval pathways are all still years away.

Nevertheless, the direction of travel is unmistakably clear. Every major obstacle facing psychedelic medicine — supply, production cost, consistency, novel compound development — has a potential solution in this kind of plant platform. Furthermore, the fact that the solution involves a tobacco plant is one of the better ironies in modern science. The plant most associated with addiction and preventable death may yet play a role in healing some of the mental health conditions that our era struggles with most.

The Study at a Glance